Is Pfizer making up for lack of innovation?
Pfizer’s penchant for big deals has culminated in a mega deal with Wyeth. Pfizer has agreed to pay $68 billion to acquire its long-time US-based rival in the largest pharmaceutical deal in nearly a decade.
Jeff Kindler, Pfizer’s top boss, had said just last year that big deals could be “very disruptive.” However, the company is at it again.
Observers maintain that as in the past, the coming together of two large… Continue reading
